Rapha Capital Management, LLC
Venture capitalSurfside · Seed–Series A · 1 people tracked
Also known as Rapha Capital Bioventures · Rapha Capital PE Life Sciences
Investment thesis
Rapha Capital Management concentrates on discovering potentially disruptive biopharmaceutical companies among a broad field of less compelling opportunities. The firm aims to identify and nurture revolutionary ideas across medicine, healthcare and technology, seeking to recognize their value earlier than other investors.
Source: firm website, verified Aug 3, 2026.
Team · 1 people
from public directories
What they invest in
from 17 of 22 portfolio companiesBiotech ×14Healthtech ×7Longevity ×7Deep Tech ×5Medical Devices ×2New Materials ×2Advanced Manufacturing ×1AI & Machine Learning ×1
HQs:United States×13
Investments · 22 tracked
founders shown can be your intro pathBy year:2026 · 12020 · 12 dated
PartnerKevin M. Slawin· solo GP
Biopharmaceutical company using computational biology to identify and develop novel peptide therapies, including AXT107 for retinal/eye diseases.
BiotechBethesda, US
Aleksander S. Popel, PhD(Executive Officer, Director)Jordan J. Green(Executive Officer, Director)Wendy Perrow(Executive Officer, Director)
PartnerKevin M. Slawin· solo GP
PartnerKevin M. Slawin· solo GP
PartnerKevin M. Slawin· solo GP
Clinical-stage biopharmaceutical company developing controllable cell therapies, including next-generation CAR-T, TCR and allogeneic T cell products such as rivo-cel and the GoCAR-T candidate BPX-601.
PartnerKevin M. Slawin· solo GP
DELiver Therapeutics develops small molecule and peptide therapeutics using high-throughput DNA encoded library (DEL) drug screening to address challenging and previously "undruggable" targets in clinical medicine, with a focus on tyrosine kinase targets.
BiotechDeep TechHealthtechLongevityHouston, US
Kevin Slawin(Founder)
PartnerKevin M. Slawin· solo GP
Ponce Aurora (deliverthera.com) develops small molecule kinase inhibitors discovered through DNA-encoded library (DEL) screening, including a multi-kinase inhibitor targeting ABL1-T315I and other tyrosine kinases for patients with Ph+ acute lymphocytic leukemia.
BiotechDeep TechLongevity
PartnerKevin M. Slawin· solo GP
Demeetra is a genome engineering company that develops precision gene-editing platforms — including Cas-CLOVER, Harbor-IN and Super piggyBac transposases and CleanCut CHO host cell lines — along with integrated cell line development and GMP manufacturing services.
BiotechDeep TechHealthtechLexington, US
Jack Crawford(CEO)
PartnerKevin M. Slawin· solo GP
BiotechHouston, US
Kevin Mark Slawin(Executive Officer, Director)
BoardJerold Winograd(Director)Frank Bartlett McGuyer(Director)
PartnerKevin M. Slawin· solo GP
FIZE Medical develops an automated digital platform for fluid management in clinical settings, using real-time data to support clinical decision-making.
AI & Machine LearningDigital HealthHealthtechMedical Devices
Noam Levine(Founder)
PartnerKevin M. Slawin· solo GP
BiotechAuburndale, US
John Vacha(Executive Officer, Director)Ken Daignault(Director)Chris Bleck(Director)Jim Hutchens(Executive Officer, Director)Robin Atlas(Director)
PartnerKevin M. Slawin· solo GP
K2bio is a contract research organization offering in vivo study design, execution, and analysis in an AAALAC-accredited vivarium, along with in vitro research and pharmacology services for biotech and pharmaceutical partners.
BiotechHealthtechHouston, US
Andrew DeSomma(Member of the Board of Directors)Gerard Fleury(Member of the Board of Directors)Clifford J. Stocks(Member of the Board of Directors)Andrew Strong(Member of the Board of Directors)Daniel Clark(Chief Financial Officer)Kevin Slawin(Member of the Board of Directors)
PartnerKevin M. Slawin· solo GP
BiotechGaithersburg, US
Jonathan Schneck(Director)Alain Cappeluti(Executive Officer, Director)Kenneth Carter(Executive Officer, Director)
BoardJanis Naeve(Director)James Barrett(Director)
PartnerKevin M. Slawin· solo GP
Numat develops metal-organic frameworks (MOFs) and manufactures them at industrial scale through an integrated campus with ISO 9001:2015 certified quality management.
Advanced ManufacturingCleantechDeep TechNew MaterialsIllinois, US
Ben Hernandez(Founder and Chief Executive Officer)Dr. Omar Farha(Founder and Chief Scientific Officer)T. Jay Collins(Director)Bill Kroll(Director)Luka Erceg(Director)Jeff Klunzinger(Director)
PartnerKevin M. Slawin· solo GP
Perseus SENOLYTIX is an oncology company developing MitoXcel oncopeptides, sequence-engineered peptides that target cancer cells through mitochondrial membrane potential rather than receptor- or kinase-based mechanisms.
BiotechDeep TechLongevity
PartnerKevin M. Slawin· solo GP
Phoenix SENOLYTIX is a longevity biotech developing controllable gene therapies that target the biological mechanisms of aging, based on its ApoptiCIDe-CE and ApoptiCIDe-RGT platforms and a proprietary cell-elimination switch triggered by a reformulated small molecule.
BiotechHealthtechLongevityHouston, US
PartnerKevin M. Slawin· solo GP
Ponce Aurora is a longevity company, affiliated with GEROTHERAPEUTIX, that develops cosmetics, beverages, and supplements designed to counteract aging and boost energy using licensed MitoXcel geropeptide technology.
BiotechLongevityWellness & Fitness
PartnerKevin M. Slawin· solo GP
Ponce Aurora is a longevity company developing cosmetics, beverages, and supplements that target aging-related cellular issues using proprietary geropeptide technology.
ConsumerHealthtechLongevity
PartnerKevin M. Slawin· solo GP
BiotechSan Diego, US
Eric Ostertag(Executive Officer, Director)Mark Gergen(Executive Officer, Director)
BoardAdrian Howd(Director)David Hirsch(Director)
PartnerKevin M. Slawin· solo GP
PrintBio is a clinical- and commercial-stage biotechnology company developing 3D-bioprinting and material science technologies to create bioresorbable surgical mesh products, including its DynaFlex and DynaForm Programmable Surgical Mesh lines for soft tissue repair and reinforcement.
BiotechMedical DevicesNew Materials
PartnerKevin M. Slawin· solo GP
Senotherapeutix (d/b/a Gerotherapeutix) develops gerotherapeutics based on its MitoXcel geropeptide platform, which targets mitochondrial mechanisms of cellular aging to improve healthspan and extend lifespan.
BiotechHealthtechLongevityHouston, US
Dr. Slawin(Founder & Leader)
PartnerKevin M. Slawin· solo GP
San Diego, US
John McIntyre(Executive Officer, Director)John Zdanowski(Executive Officer, Director)
BoardRalph Mack(Director)
PartnerKevin M. Slawin· solo GP
Portfolio news
latest coverage across their companiesEos SENOLYTIX · minichart.com.sg · May 15, 2026
Numat Technologies · trysignalbase.com · May 27, 2025
Frequently asked questions
- What stage does Rapha Capital Management, LLC invest at?
- Rapha Capital Management, LLC invests at the Seed, Series A stages.
- What sectors does Rapha Capital Management, LLC focus on?
- Rapha Capital Management, LLC focuses on AgTech, Biotech, Healthtech, Medical Devices.
- Where is Rapha Capital Management, LLC located?
- Rapha Capital Management, LLC is headquartered in Surfside, US.
Similar investors
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Granatus Ventures is a venture capital firm that backs startups worldwide leveraging Armenia's potential as an emerging technology hub.
Innovestor is a Nordic investment group operating across venture capital, life science, real estate, energy storage, and corporate venturing platforms, and is among the most active early-stage investors in the region.
Lerer Hippeau is an early-stage venture capital firm that backs founders across sectors, emphasizing investing in companies before they gain wider recognition.
BioGenerator Ventures creates, builds, and invests in life sciences companies working on problems in human health and agriculture, pairing capital with company-building resources through BioGenerator Labs.